TY  - JOUR
AU  - Kardell, Oliver
AU  - Gronauer, Thomas
AU  - von Toerne, Christine
AU  - Merl-Pham, Juliane
AU  - König, Ann-Christine
AU  - Barth, Teresa K
AU  - Mergner, Julia
AU  - Ludwig, Christina
AU  - Tüshaus, Johanna
AU  - Giesbertz, Pieter
AU  - Breimann, Stephan
AU  - Schweizer, Lisa
AU  - Müller, Torsten
AU  - Kliewer, Georg
AU  - Distler, Ute
AU  - Gomez-Zepeda, David
AU  - Popp, Oliver
AU  - Qin, Di
AU  - Teupser, Daniel
AU  - Cox, Jürgen
AU  - Imhof, Axel
AU  - Küster, Bernhard
AU  - Lichtenthaler, Stefan F
AU  - Krijgsveld, Jeroen
AU  - Tenzer, Stefan
AU  - Mertins, Philipp
AU  - Coscia, Fabian
AU  - Hauck, Stefanie M
TI  - Multicenter Longitudinal Quality Assessment of MS-Based Proteomics in Plasma and Serum.
JO  - Journal of proteome research
VL  - 24
IS  - 3
SN  - 1535-3893
CY  - Washington, DC
PB  - ACS Publications
M1  - DZNE-2025-00404
SP  - 1017 - 1029
PY  - 2025
AB  - Advancing MS-based proteomics toward clinical applications evolves around developing standardized start-to-finish and fit-for-purpose workflows for clinical specimens. Steps along the method design involve the determination and optimization of several bioanalytical parameters such as selectivity, sensitivity, accuracy, and precision. In a joint effort, eight proteomics laboratories belonging to the MSCoreSys initiative including the CLINSPECT-M, MSTARS, DIASyM, and SMART-CARE consortia performed a longitudinal round-robin study to assess the analysis performance of plasma and serum as clinically relevant samples. A variety of LC-MS/MS setups including mass spectrometer models from ThermoFisher and Bruker as well as LC systems from ThermoFisher, Evosep, and Waters Corporation were used in this study. As key performance indicators, sensitivity, precision, and reproducibility were monitored over time. Protein identifications range between 300 and 400 IDs across different state-of-the-art MS instruments, with timsTOF Pro, Orbitrap Exploris 480, and Q Exactive HF-X being among the top performers. Overall, 71 proteins are reproducibly detectable in all setups in both serum and plasma samples, and 22 of these proteins are FDA-approved biomarkers, which are reproducibly quantified (CV < 20
KW  - Humans
KW  - Proteomics: methods
KW  - Proteomics: standards
KW  - Tandem Mass Spectrometry: standards
KW  - Tandem Mass Spectrometry: methods
KW  - Longitudinal Studies
KW  - Chromatography, Liquid: methods
KW  - Reproducibility of Results
KW  - Biomarkers: blood
KW  - Blood Proteins: analysis
KW  - Plasma: chemistry
KW  - Serum: chemistry
KW  - LC-MS/MS (Other)
KW  - R package mpwR (Other)
KW  - clinical specimen (Other)
KW  - longitudinal round-robin study (Other)
KW  - plasma (Other)
KW  - serum (Other)
KW  - Biomarkers (NLM Chemicals)
KW  - Blood Proteins (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:39918541
DO  - DOI:10.1021/acs.jproteome.4c00644
UR  - https://pub.dzne.de/record/277421
ER  -